People who started using GLP-1 drugs, including liraglutide, semaglutide, dulaglutide, exenatide, lixisenatide or albiglutide, were about 10% less likely to make an emergency department (ED) visit in the following year than those who started topiramate, data shows
Context matters: baseline diet, microbiome composition, and individual metabolic factors influence whether a persons TMAO rises meaningfully
Treatment was well-tolerated, with nausea being the most common side effect (5% discontinuation rate)
It enhances the bodys regenerative and anabolic capacity , especially when combined with strength training, adequate nutrition, and recovery
Heart rate changes, though typically modest with GLP-1 therapy, deserve documentation if symptomatic